Medicine and Dentistry
Uterine Cancer
100%
Recurrent Disease
73%
Neoplasm
67%
Retroperitoneal Lymph Node Dissection
54%
Lymph Node Metastasis
41%
Granulosa Cell Tumour
36%
Metastatic Carcinoma
28%
Pelvis
28%
Diseases
27%
Overall Survival
26%
Disease Free Survival
26%
Prognostic Factor
25%
Lymph Node
22%
Adjuvant Therapy
20%
Ovarian Tumor
19%
Gynecological Oncology
19%
Progression Free Survival
19%
Malignant Neoplasm
16%
CA-125
15%
Cervical Cancer
15%
Vulvar Cancer
14%
Uterine Serous Carcinoma
14%
Ascites Fluid Cytology
14%
Lymph Duct
13%
Endometrium Carcinoma
11%
Adjuvant Radiotherapy
11%
Hysterectomy
11%
Univariate Analysis
10%
Squamous Cell
10%
Multivariate Analysis
10%
Surgery
10%
Disease Specific Survival
10%
Laparotomy
9%
Radiation Therapy
9%
Sentinel Lymph Node
9%
Salpingooophorectomy
9%
Recurrence Risk
9%
Paraaortic Lymph Node
9%
Carcinosarcoma
9%
Neoadjuvant Chemotherapy
9%
Gynecology
8%
Adenocarcinoma
7%
Hyperplasia
7%
Biopsy Technique
7%
Survival Analysis
7%
Survival Rate
6%
Radical Surgery
6%
Clear Cell
6%
Predictive Factor
5%
Female Genital Tract Cancer
5%
Keyphrases
Endometrial Cancer
70%
Lymphadenectomy
36%
Lymph Node Metastasis
35%
Adult Granulosa Cell Tumor
31%
Disease-free Survival
26%
Tumor
25%
Overall Survival
23%
Endometrioid Endometrial Cancer
22%
Progression-free Survival
21%
Adjuvant Therapy
20%
Metastasis
17%
Tumor Size
17%
Staged Surgery
16%
Endometrioid
15%
Frozen Section
15%
Independent Prognostic Factor
14%
Peritoneal Cytology
14%
Multicentric
14%
Para-aortic Lymphadenectomy
14%
Granular Cell Tumor
13%
Uterine Serous Carcinoma
13%
Single Center
13%
Univariate Analysis
13%
Recurrence Rate
13%
Prognostic Factors
13%
Disease-specific Survival
12%
Multivariate Analysis
12%
Borderline Tumor
12%
Post-recurrence Survival
12%
Follow-up Time
11%
Adjuvant Radiotherapy
11%
Ovarian Tumor
11%
High-risk Endometrial Cancer
11%
Cancer Patients
11%
Endometrial Carcinoma
11%
Carbohydrate Antigen 125 (CA125)
10%
Vulvar Cancer
10%
Lymphovascular Invasion
10%
CA-125 Levels
10%
Salpingo-oophorectomy
10%
Menopausal Status
9%
Residual Tumor
9%
Intermediate Risk
9%
Factors Predicting
9%
Obstetrics
9%
Sentinel Lymph Node
9%
Recurrence Prediction
9%
Gynecologic Surgery
9%
Multi-institutional Analysis
9%
Stage IVB
9%